# US 2020/0402633 A1 · Dynamic equivalent on board estimator

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0402633 A1
- Document ID: US20200402633A1
- Status: Published application
- Kind: A1
- Application number: 16/906,812
- Filed: 2020-06-19
- Published: 2020-12-24
- Earliest claimed: 2019-06-19
- Assignees: DexCom, Inc.
- Applicants: DexCom, Inc.
- Inventors: Stephen D. Patek; Enrique Campos-Náñez
- Web page: https://patentgrep.com/patent/US20200402633A1

## CPC

- G16H 20/17: delivered via infusion or injection
- G06N 5/04: Inference or reasoning models
- G16H 10/60: for patient-specific data, e.g. for electronic patient records
- G16H 20/10: relating to drugs or medications, e.g. for ensuring correct administration to patients
- G16H 20/30: relating to physical therapies or activities, e.g. physiotherapy, acupressure or exercising
- G16H 20/60: relating to nutrition control, e.g. diets
- G16H 40/67: for remote operation
- G16H 50/20: for computer-aided diagnosis, e.g. based on medical expert systems
- G16H 50/30: for calculating health indices; for individual health risk assessment
- G16H 50/50: for simulation or modelling of medical disorders
- G16H 50/70: for mining of medical data, e.g. analysing previous cases of other patients
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G06N: COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS

## Abstract

Adaptive on board estimation of exogenous pharmacon responsive to transient (i.e., impermanent) physiological effects is provided. Dynamically estimating an equivalent amount of an exogenous pharmacon on board (XOB), such as insulin and/or carbohydrates, left in the subject, is based on predictions of glucose time-series data. These estimated values, such as insulin on board (IOB), are useful for diabetes management software, including decision support and/or artificial pancreas (AP) algorithms, for example.

## Claims

### Claim 1

A system comprising:
an input compiler configured to receive and process input data;
an exogenous pharmacon on board (XOB) estimator; and
an output compiler.

### Claim 2 (depends on 1)

The system of claim 1; wherein the input data corresponds to glucose concentration readings provided by a continuous glucose monitoring (CGM) system, insulin injection/infusion data, data on ingested meals, glucagon or other pharmacon dose and/or injection data, exercise data, or stress data.

### Claim 3 (depends on 1)

The system of claim 1, wherein the input data comprises data pertaining to at least one of insulin or carbohydrates.

### Claim 4 (depends on 1)

The system of claim 1, further comprising at least one of: a continuous glucose monitoring (CGM) system in communication with the input compiler and configured to provide the input data to the input compiler; or a closed-loop delivery system in communication with the input compiler and configured to provide the input data to the input compiler, wherein the input data comprises a sequence of insulin dose recommendations or glucagon dose recommendations.

### Claim 5 (depends on 1)

The system of claim 1; wherein the input compiler is configured to compile at least one of (1) data related to a pharmacon whose glucose-effect equivalent is being compiled or (2) data related to the relevant history of continuous glucose monitoring (CGM) system readings.

### Claim 6 (depends on 1)

The system of claim 1, wherein the output compiler is an XOB output compiler configured to render an XOB estimation, wherein the XOB estimation comprises at least one of an insulin on board (IOB) estimation or a carbohydrates on board (COB) estimation.

### Claim 7 (depends on 1)

The system of claim 1, wherein the XOB estimator is configured to estimate the glucose equivalent effect of the pharmacon at a predetermined time.

### Claim 8 (depends on 1)

The system of claim 1, wherein the XOB estimator comprises a baseline time-series estimator, an iterative time-series comparator, and a time-series comparator, wherein the baseline time-series estimator is a stateless machine that receives historical XOB amounts and continuous glucose monitoring (CGM) system history and produces a time-series that approximates future values of glucose, wherein the iterative time-series comparator is configured to combine a procedure that generates candidate XOB amounts with a modification of the time-series estimator in which historical XOB amounts are substituted with the XOB amount under consideration, wherein the time-series comparator is configured to match a pair of time-series that can be any measure of distance or similarity between the series.

### Claim 9

A system comprising:
an input compiler, wherein the input compiler receives and processes input data relating to a pharmacon;
an exogenous pharmacon on board (XOB) estimator, wherein the XOB estimator uses estimation to account for transient changes in pharmacon absorption of the pharmacon, and wherein the XOB estimator determines an XOB estimation; and
an output compiler, wherein the output compiler renders the XOB estimation.

### Claim 10 (depends on 9)

The system of claim 9, wherein the transient changes in pharmacon absorption are determined by data from a continuous glucose monitoring (CGM) system.

### Claim 11 (depends on 9)

The system of claim 9, wherein the pharmacon is insulin or carbohydrates, and wherein the XOB estimation comprises an insulin on board (IOB) estimation or a carbohydrates on board (COB) estimation.

### Claim 12 (depends on 9)

The system of claim 9, wherein the input data corresponds to glucose concentration readings provided by a continuous glucose monitoring (CGM) system, insulin injection/infusion data, data on ingested meals, glucagon or other pharmacon dose and/or injection data, exercise data, or stress data.

### Claim 13 (depends on 9)

The system of claim 9, wherein the input data comprises data pertaining to at least one of insulin or carbohydrates, or a sequence of insulin dose recommendations or glucagon dose recommendations.

### Claim 14 (depends on 9)

The system of claim 9, further comprising a continuous glucose monitoring (CGM) system in communication with the input compiler and configured to provide the input data to the input compiler.

### Claim 15 (depends on 9)

The system of claim 9, further comprising a closed-loop delivery system in communication with the input compiler and configured to provide the input data to the input compiler.

### Claim 16 (depends on 9)

The system of claim 9, wherein the input compiler is configured to compile at least one of (1) data related to a pharmacon whose glucose-effect equivalent is being compiled or (2) data related to the relevant history of continuous glucose monitoring (CGM) system readings.

### Claim 17 (depends on 9)

The system of claim 9, wherein the XOB estimator is configured to estimate the glucose equivalent effect of the pharmacon at a predetermined time.

### Claim 18 (depends on 9)

The system of claim 9, wherein the XOB estimator comprises a baseline time-series estimator, an iterative time-series comparator, and a time-series comparator, wherein the baseline time-series estimator is a stateless machine that receives historical XOB amounts and continuous glucose monitoring (CGM) system history and produces a time-series that approximates future values of glucose, wherein the iterative time-series comparator is configured to combine a procedure that generates candidate XOB amounts with a modification of the time-series estimator in which historical XOB amounts are substituted with the XOB amount under consideration, wherein the time-series comparator is configured to match a pair of time-series that can be any measure of distance or similarity between the series.

### Claim 19

A system comprising:
a monitoring device configured to receive input data pertaining to a patient;
a handheld computing device configured to receive the input data from the monitoring device; and
an exogenous pharmacon on board (XOB) calculator configured to perform an XOB estimation using the input data.

### Claim 20 (depends on 19)

The system of claim 19, wherein the XOB calculator is locally implemented on a computing device or is implemented on a cloud computing device.

### Claim 21 (depends on 19)

The system of claim 19, wherein the monitoring device comprises an insulin pen.

### Claim 22 (depends on 19)

The system of claim 19, further comprising an insulin pen configured to provide additional input data to the handheld computing device, wherein the XOB calculator is configured to perform the XOB estimation using the input data and the additional input data.

### Claim 23 (depends on 19)

The system of claim 19, wherein the XOB calculator is further configured to render the XOB estimation via a display of the handheld computing device.

### Claim 24 (depends on 19)

The system of claim 19, further comprising an insulin pump configured to receive data from the handheld computing device and provide an amount of insulin to the patient based on the data received from the handheld computing device.

### Claim 25 (depends on 19)

The system of claim 19, wherein the input data corresponds to glucose concentration readings provided by a continuous glucose monitoring (CGM) system, insulin injection/infusion data, data on ingested meals, glucagon or other pharmacon dose and/or injection data, exercise data, or stress data.

### Claim 26 (depends on 19)

The system of claim 19, wherein the input data comprises data pertaining to at least one of insulin or carbohydrates, or a sequence of insulin dose recommendations or glucagon dose recommendations.

### Claim 27 (depends on 19)

The system of claim 19, wherein the XOB estimation comprises at least one of an insulin on board (JOB) estimation or a carbohydrates on board (COB) estimation.

### Claim 28 (depends on 19)

The system of claim 19, wherein the XOB calculator comprises an XOB estimator, wherein the XOB estimator is configured to estimate a glucose equivalent effect of a pharmacon at a predetermined time.

### Claim 29 (depends on 28)

The system of claim 28, wherein the XOB estimator comprises a baseline time-series estimator, an iterative time-series comparator, and a time-series comparator, wherein the baseline time-series estimator is a stateless machine that receives historical XOB amounts and continuous glucose monitoring (CGM) system history and produces a time-series that approximates future values of glucose, wherein the iterative time-series comparator is configured to combine a procedure that generates candidate XOB amounts with a modification of the time-series estimator in which historical XOB amounts are substituted with the XOB amount under consideration, wherein the time-series comparator is configured to match a pair of time-series that can be any measure of distance or similarity between the series.
